Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Wallentin L, et al. Among authors: braun oo. Eur Heart J. 2008 Jan;29(1):21-30. doi: 10.1093/eurheartj/ehm545. Epub 2007 Nov 30. Eur Heart J. 2008. PMID: 18055486 Clinical Trial.
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L. Erlinge D, et al. Among authors: braun oo. J Am Coll Cardiol. 2008 Dec 9;52(24):1968-77. doi: 10.1016/j.jacc.2008.07.068. J Am Coll Cardiol. 2008. PMID: 19055987 Free article. Clinical Trial.
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A. Varenhorst C, et al. Among authors: braun oo. Am Heart J. 2009 Mar;157(3):562.e1-9. doi: 10.1016/j.ahj.2008.11.021. Epub 2009 Feb 6. Am Heart J. 2009. PMID: 19249429 Clinical Trial.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Varenhorst C, et al. Among authors: braun oo. Eur Heart J. 2009 Jul;30(14):1744-52. doi: 10.1093/eurheartj/ehp157. Epub 2009 May 9. Eur Heart J. 2009. PMID: 19429918 Free PMC article. Clinical Trial.
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C. Braun OÖ, et al. Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5. Thromb Haemost. 2013. PMID: 24009042 Clinical Trial.
68 results